Interstitial Lung Disease Induced by Pazopanib Treatment for Metastatic Renal Cell Carcinoma at the Time of COVID-19 Pandemic

Valentina Orlando, Marco Francesco Maria Cavallaro, Stefano Moroso, Mario Cirino, Umberto Basso and Alessandra Guglielmi

Department of Oncology, Ospedale Maggiore, Piazza dell’Ospitale 1, Italy Department of Radiology, Ospedale Maggiore, Piazza dell’Ospitale 1, Italy Department of Pharmacy, Ospedale Maggiore, Piazza dell’Ospitale 1, Italy Medical Oncology Unit, Istituto Oncologico Veneto, Italy

^*Correspondance to: Valentina Orlando 

 PDF  Full Text Case Report | Open Access

Abstract:

Interstitial lung disease is a reported complication of therapy with tyrosine kinase inhibitors. Pazopanib, a vascular endothelial growth factor inhibitor approved for first line treatment in metastatic renal cell cancer and second line therapy for advanced sarcoma, is rarely associated with lung complications. However, interstitial lung damage is the major problem associated with coronavirus pandemic and the cause of severe respiratory syndrome. We describe the development of pneumonitis in a patient with metastatic renal cell carcinoma treated with pazopanib during the peak of coronavirus disease in Italy. This report notifies the possible onset of pazopanib induced pneumonitis and how to diagnose and manage drug induced interstitial lung disease during the pandemic of coronavirus.

Keywords:

Interstitial lung disease; Pneumonitis; Coronavirus; Renal cell carcinoma; Pazopanib

Cite the Article:

Orlando V, Francesco Maria CM, Stefano M, Mario C, Umberto B, Alessandra G. Interstitial Lung Disease Induced by Pazopanib Treatment for Metastatic Renal Cell Carcinoma at the Time of COVID-19 Pandemic. Ann Clin Case Rep. 2021; 6: 1913..